Science stands "at the very beginning of understanding the complexity" of the gut microbiome, Synthetic Biologics Inc. CEO Jeffrey Riley told BioWorld Today, noting that his company engages in "more traditional drug discovery and development vs. what Seres [Therapeutics Inc.] is doing, which is more on the cutting edge" – an edge where complexity can take its toll. And did.